B-9430 was developed by Gera at the Stewart laboratory1 and is a stable, potent, and long lastingBradykinin (BK) antagonist, a candidate anti-inflammatory drug. B-9430 shows potency at bradykinin B2 (pA2 = 8.6) and B1 receptors (pA2 = 7.3). Bradykinin is an important growth factor for small-cell lung cancer (SCLC) and prostate cancer (PC). BK receptors are expressed on almost all lung cancer cell lines and on many PC cells. B-9430 is very resistant to kinases and thus shows a very long action in vivo. This peptide is unique among bradykinin antagonists in that it is active after oral administration.
Stable, potent, and long lastingBradykinin (BK) antagonist, which shows high BK antagonism on both B-1 and B-2 receptors.
Caution
Product is air and light sensitive. Store in the dark.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.